Annual EBITDA
-$222.61 M
-$55.71 M-33.38%
31 December 2023
Summary:
Crinetics Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization is currently -$222.61 million, with the most recent change of -$55.71 million (-33.38%) on 31 December 2023. During the last 3 years, it has fallen by -$148.60 million (-200.80%). CRNX annual EBITDA is now -3662.81% below its all-time high of -$5.92 million, reached on 31 December 2016.CRNX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$87.03 M
-$5.00 M-6.09%
30 September 2024
Summary:
Crinetics Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization is currently -$87.03 million, with the most recent change of -$5.00 million (-6.09%) on 30 September 2024. Over the past year, it has dropped by -$28.32 million (-48.25%). CRNX quarterly EBITDA is now -5272.04% below its all-time high of -$1.62 million, reached on 30 June 2017.CRNX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$304.51 M
-$28.32 M-10.26%
30 September 2024
Summary:
Crinetics Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization is currently -$304.51 million, with the most recent change of -$28.32 million (-10.26%) on 30 September 2024. Over the past year, it has dropped by -$98.12 million (-47.54%). CRNX TTM EBITDA is now -11716.38% below its all-time high of -$2.58 million, reached on 31 March 2017.CRNX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CRNX EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -33.4% | -48.3% | -47.5% |
| 3 y3 years | -200.8% | -215.6% | -211.7% |
| 5 y5 years | -688.3% | -480.1% | -545.4% |
CRNX EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -200.8% | at low | -215.6% | at low | -211.7% | at low |
| 5 y | 5 years | -688.3% | at low | -480.8% | at low | -545.4% | at low |
| alltime | all time | -3662.8% | at low | -5272.0% | at low | <-9999.0% | at low |
Crinetics Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$87.03 M(+6.1%) | -$304.51 M(+10.3%) |
| June 2024 | - | -$82.03 M(+12.3%) | -$276.19 M(+11.9%) |
| Mar 2024 | - | -$73.06 M(+17.1%) | -$246.87 M(+11.4%) |
| Dec 2023 | -$222.61 M(+33.4%) | -$62.40 M(+6.3%) | -$221.51 M(+7.3%) |
| Sept 2023 | - | -$58.70 M(+11.4%) | -$206.39 M(+8.1%) |
| June 2023 | - | -$52.72 M(+10.5%) | -$190.89 M(+5.5%) |
| Mar 2023 | - | -$47.70 M(+0.9%) | -$181.01 M(+8.5%) |
| Dec 2022 | -$166.90 M(+56.3%) | -$47.28 M(+9.4%) | -$166.90 M(+11.1%) |
| Sept 2022 | - | -$43.21 M(+0.9%) | -$150.28 M(+11.6%) |
| June 2022 | - | -$42.83 M(+27.5%) | -$134.64 M(+14.4%) |
| Mar 2022 | - | -$33.59 M(+9.6%) | -$117.67 M(+10.2%) |
| Dec 2021 | -$106.78 M(+44.3%) | -$30.65 M(+11.2%) | -$106.78 M(+9.3%) |
| Sept 2021 | - | -$27.57 M(+6.6%) | -$97.69 M(+10.6%) |
| June 2021 | - | -$25.86 M(+13.9%) | -$88.33 M(+11.6%) |
| Mar 2021 | - | -$22.69 M(+5.2%) | -$79.15 M(+7.0%) |
| Dec 2020 | -$74.00 M | -$21.57 M(+18.4%) | -$74.00 M(+9.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2020 | - | -$18.21 M(+9.1%) | -$67.42 M(+5.0%) |
| June 2020 | - | -$16.68 M(-4.9%) | -$64.22 M(+5.9%) |
| Mar 2020 | - | -$17.55 M(+17.1%) | -$60.65 M(+14.5%) |
| Dec 2019 | -$52.95 M(+87.5%) | -$14.98 M(-0.1%) | -$52.95 M(+12.2%) |
| Sept 2019 | - | -$15.00 M(+14.4%) | -$47.18 M(+17.6%) |
| June 2019 | - | -$13.12 M(+33.2%) | -$40.11 M(+23.0%) |
| Mar 2019 | - | -$9.84 M(+6.7%) | -$32.60 M(+15.5%) |
| Dec 2018 | -$28.24 M(+213.8%) | -$9.22 M(+16.3%) | -$28.24 M(+31.6%) |
| Sept 2018 | - | -$7.93 M(+41.4%) | -$21.47 M(+35.1%) |
| June 2018 | - | -$5.61 M(+2.4%) | -$15.89 M(+33.5%) |
| Mar 2018 | - | -$5.48 M(+123.6%) | -$11.90 M(+32.2%) |
| Dec 2017 | -$9.00 M(+52.1%) | -$2.45 M(+4.2%) | -$9.00 M(+37.4%) |
| Sept 2017 | - | -$2.35 M(+45.2%) | -$6.55 M(+56.0%) |
| June 2017 | - | -$1.62 M(-37.1%) | -$4.20 M(+62.9%) |
| Mar 2017 | - | -$2.58 M | -$2.58 M |
| Dec 2016 | -$5.92 M | - | - |
FAQ
- What is Crinetics Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Crinetics Pharmaceuticals?
- What is Crinetics Pharmaceuticals annual EBITDA year-on-year change?
- What is Crinetics Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Crinetics Pharmaceuticals?
- What is Crinetics Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Crinetics Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Crinetics Pharmaceuticals?
- What is Crinetics Pharmaceuticals TTM EBITDA year-on-year change?
What is Crinetics Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of CRNX is -$222.61 M
What is the all time high annual EBITDA for Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is -$5.92 M
What is Crinetics Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, CRNX annual earnings before interest, taxes, depreciation & amortization has changed by -$55.71 M (-33.38%)
What is Crinetics Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of CRNX is -$87.03 M
What is the all time high quarterly EBITDA for Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$1.62 M
What is Crinetics Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, CRNX quarterly earnings before interest, taxes, depreciation & amortization has changed by -$28.32 M (-48.25%)
What is Crinetics Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of CRNX is -$304.51 M
What is the all time high TTM EBITDA for Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is -$2.58 M
What is Crinetics Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, CRNX TTM earnings before interest, taxes, depreciation & amortization has changed by -$98.12 M (-47.54%)